We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Angioshield First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02072239
First Posted: February 26, 2014
Last Update Posted: January 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Neograft Technologies, Incorporated
  Purpose
The purpose of this study is to determine whether or not the Angioshield device can be safely applied to support saphenous vein grafts used in standard coronary bypass surgery.

Condition Intervention
Coronary Artery Disease Device: Angioshield

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy of the Angioshield System to Provide Mechanical Support for Vein Grafts Used in CABG Surgery

Further study details as provided by Neograft Technologies, Incorporated:

Primary Outcome Measures:
  • MACE [ Time Frame: 30 days ]
    The primary objective of this study is to provide acute and subacute (up to 30 days) safety outcomes to support expansion to a pivotal study involving a larger subject population. All Major Adverse Cardiac Events (MACE), defined as the composite of cardiac death, myocardial infarction (Q-wave and non-Q wave), and target vessel revascularization, will be evaluated at 30 days post-operative.


Secondary Outcome Measures:
  • MACE and Graft Patency [ Time Frame: 30, 90 and 365 Days ]
    The secondary objective of this study is to assess long term (up to 1 year) safety outcomes and vein patency for additional safety and preliminary efficacy information. All MACE, defined as the composite of cardiac death, myocardial infarction (Q-wave and non-Q wave), and target vessel revascularization will be evaluated at 90 and 365 days and to assess patency of the treated saphenous vein graft at 30, 90 and 365 days


Enrollment: 13
Study Start Date: February 2014
Study Completion Date: July 2015
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Device Applied
All participants will be treated with the Angioshield
Device: Angioshield
The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.

Detailed Description:
\This is a first in human study which is intended to determine if a larger pivotal study is justified.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subject will be eligible for inclusion in the investigation if he/she:

  • is between the ages of 18 and 80 years of age, inclusive
  • requires Coronary Atery Bypass Graft (CABG) surgery with minimum of one SVG used to bypass a stenosis in the Right Coronary, the Circumflex, a Diagonal, or an Obtuse Marginal artery, due to atherosclerotic coronary artery disease
  • is able to give their informed written consent
  • is willing and able to complete all follow-up visits and procedures

Exclusion Criteria:

Subject will be excluded from participation in the investigation if he/she:

  • is currently enrolled in another clinical investigation
  • is unable to tolerate or comply with required post-surgical medications or imaging (e.g., anticoagulation regimen; or known allergy to contrast agent)
  • is or may be pregnant or is lactating, or plans to become pregnant in the next 12 months
  • shows a presence of hypercoagulable state or history of idiopathic venous or arterial thrombosis
  • has had an acute MI within the last 21 days
  • has had a previous CABG
  • requires emergency surgery
  • has a left ejection fraction (LEF) less than 20%
  • has a target vessel stenosis of less than 70%
  • has a transmural infarct of the target artery territory
  • currently requiring dialysis
  • is having concomitant-surgery of any kind
  • has varicose veins
  • has had previous saphenectomy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02072239


Locations
Poland
Pope John Paul II Hospital
Krakow, Poland
Sponsors and Collaborators
Neograft Technologies, Incorporated
Investigators
Principal Investigator: Jerzy Sadowski, MD, PhD Pope John Paul II Hospital and Cardiology Collegium Medicum Jagiellonian University, Krakow, Poland
  More Information

Responsible Party: Neograft Technologies, Incorporated
ClinicalTrials.gov Identifier: NCT02072239     History of Changes
Other Study ID Numbers: TP11-002
First Submitted: February 13, 2014
First Posted: February 26, 2014
Last Update Posted: January 13, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Neograft Technologies, Incorporated:
CABG
Intimal Hyperplasia
Atherosclerosis
Myocardial Infarction

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases